efgartigimod alfa + hyaluronidase-qvfc

Efgartigimod alfa + hyaluronidase-qvfc is a fixed-dose combination biologic drug administered as a subcutaneous injection for the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults[2][6][10]. The combination consists of two components: - Efgartigimod alfa, a human IgG1 antibody fragment engineered to bind with high affinity to the neonatal Fc receptor (FcRn), thereby blocking FcRn-mediated recycling of IgG. This results in accelerated degradation and reduced levels of circulating IgG antibodies, including pathogenic autoantibodies implicated in gMG and CIDP[5][7]. - Hyaluronidase (human recombinant), which transiently increases subcutaneous tissue permeability by depolymerizing hyaluronan, facilitating rapid absorption of co-administered drugs[5]. The reduction in pathogenic IgG autoantibodies leads to clinical improvement in diseases where such antibodies play a central role. The product is marketed under the brand name Vyvgart Hytrulo and was developed by Argenx. It represents the first approved neonatal Fc receptor blocker for CIDP.

Brand names

Vyvgart Hytrulo

Other names

efgartigimod alfa and hyaluronidase-qvfcefgartigimod/hyaluronidase-qvfc